AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations
AstraZeneca and Eli Lilly and Company (Lilly) have announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumours.
AstraZeneca opens new manufacturing facility to support continued growth in Russia
AstraZeneca today announced the opening of its new state-of-the-art manufacturing and packaging facility in Kaluga, Russia, dedicated to the local supply of innovative medicines.
AstraZeneca supports crowd sourcing challenge to find new combination therapies for cancer
AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer.
AstraZeneca to invest £11.5 million in collaboration with The University of Manchester
AstraZeneca and The University of Manchester today announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients. The five-year agreement will see the organisations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time.
AstraZeneca and Valeant Pharmaceuticals to partner on psoriasis treatment
AstraZeneca announced that it has entered into a collaboration agreement with Valeant Pharmaceuticals International, Inc. under which it will grant an exclusive licence for Valeant to develop and commercialise brodalumab.
AstraZeneca appoints Dr Sean Bohen
AstraZeneca today announced the appointment of Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September.
AstraZeneca and Peregrine to collaborate on immuno-oncology combination clinical trial
AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736).
AstraZeneca and Heptares Therapeutics enter agreement for immuno-oncology treatment
AstraZeneca and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, today announced that they have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor…
AstraZeneca and Isis Pharmaceuticals colaborate to discover and develop antisense drugs
AstraZeneca and Isis Pharmaceuticals, Inc. have announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.
AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine
AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine.
US FDA approves AstraZeneca product for non-small cell lung cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved IRESSA (gefitinib) tablets, 250mg once daily, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.
AstraZeneca-University of Cambridge announce joint PhD and clinical research scholarships
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years, spanning translational science, basic and clinical research.
AstraZeneca reveals findings of archaeological dig as build gets underway at Cambridge
AstraZeneca has announced the findings of archaeological excavations on the Cambridge Biomedical Campus, which will be home to the company’s new, purpose-built global R&D centre and corporate headquarters from the end of 2016.
AstraZeneca collaborates with Inserm in type 2 diabetes and chronic kidney disease studies
AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches to type 2 diabetes and Chronic Kidney Disease (CKD). The aim of the collaboration is to advance understanding of the biological mechanisms that underpin these conditions and develop new treatments based on this…
AstraZeneca announces results of study into safety of diabetes therapies
AstraZeneca today announced results from an observational, retrospective study which found no evidence of increased risk of hospitalisation for heart failure (hHF) with saxagliptin, compared with sitagliptin, both of which are dipeptidyl peptidase-4 (DPP-4) inhibitors, in patients with type 2 diabetes. A similar finding was obtained when comparing the overall DPP-4 class to sulfonylureas.
AstraZeneca presents data demonstrating progress of diabetes portfolio
AstraZeneca today announced that 86 abstracts reporting results of the company’s research and development in diabetes have been accepted for presentation at the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston, 5-9 June 2015.
AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, provided an update on the progress of their combination-focused immuno-oncology pipeline at an investor science event at the American Society of Clinical Oncology (ASCO) meeting in Chicago on 1 June 2015.
AstraZeneca and MedImmune present positive immuno-oncology combination data at ASCO 2015
AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.
AstraZeneca & Lilly collaborate on Immuno-oncology clinical trial in solid tumours
AstraZeneca and Eli Lilly and Company (Lilly) today announced that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA®), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. The planned study will assess the combination…
AstraZeneca provides update on brodalumab development programme
Amgen today announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
AstraZeneca invests in new biologics manufacturing facility in Södertälje, Sweden
AstraZeneca today announced that it plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics.
AstraZeneca updates on immuno-oncology pipeline and combination treatments at ASCO 2015
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May-2 June 2015. 61 scientific abstracts2 will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination…
AstraZeneca and MHI to screen 80,000 samples for cardiovascular and diabetes genetic traits
AstraZeneca today announced a collaboration with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes
AstraZeneca & Abbott to develop companion diagnostic tests for tralokinumab in severe asthma
AstraZeneca today announced that it has entered an agreement with Abbott, a global healthcare company, to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy, tralokinumab. To date, no companion diagnostic blood tests have been approved for use in asthma.
Mene Pangalos elected to the Fellowship of the Academy of Medical Sciences
IMED leader one of 48 new fellows recognised for the advancement of medical science in the UK